This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .
Cohort
Prospective
We did not apply any interventions; only observational research was conducted.
Other interventionWe did not apply any interventions; only observational research was conducted.
Natural disease progression of various atypical parkinsonian syndromes
To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.
Click on the lead sponsor to view all of their trials.
